Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Teleflex ( (TFX) ) is now available.
On April 30, 2026, Teleflex announced that Medtronic veteran Jason Weidman will become President and CEO effective June 8, 2026, succeeding interim chief Stuart Randle, who remains on the board. Weidman, a 25-year medical device industry leader with deep experience in coronary and peripheral vascular markets, will also join the Teleflex board and receives a compensation package that includes salary, equity awards, relocation benefits and severance and change-of-control protections.
The appointment comes as Teleflex undergoes a strategic transformation centered on divestitures and a sharpened focus on interventional, critical care and high acuity hospital markets. The board highlighted Weidman’s track record in driving innovation and global growth as critical to executing the company’s go-forward strategy, while Teleflex’s planned share repurchases and debt paydown are expected to strengthen its capital structure and support its ambitions as a compelling growth story for stakeholders.
The most recent analyst rating on (TFX) stock is a Hold with a $135.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.
Spark’s Take on TFX Stock
According to Spark, TipRanks’ AI Analyst, TFX is a Neutral.
The score is held back primarily by the sharp TTM decline in earnings and cash generation, including negative free cash flow. Offsetting this, management’s guidance supports mid-single-digit pro forma growth and outlines credible balance-sheet and shareholder-return actions tied to divestiture proceeds, but near-term margin/EPS headwinds and execution timing risk remain. Technically and on valuation, signals are neutral to cautious (negative MACD; negative P/E).
To see Spark’s full report on TFX stock, click here.
More about Teleflex
Teleflex Incorporated is a global provider of medical technologies focused on improving the health and quality of people’s lives through a diverse portfolio spanning anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology solutions. The company markets well-known brands such as Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck, and aims to be a trusted partner in healthcare by leveraging purpose-driven innovation and world-class products.
Teleflex concentrates on core interventional, critical care and high acuity hospital markets, positioning itself to benefit from attractive, high-growth end markets. Following planned divestitures and associated balance sheet moves, including a substantial share buyback and debt reduction, the company expects a significantly enhanced capital structure designed to support its next phase of growth and value creation.
Average Trading Volume: 937,187
Technical Sentiment Signal: Hold
Current Market Cap: $5.9B
For an in-depth examination of TFX stock, go to TipRanks’ Overview page.